An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Low-Dose Ribavirin QD in Subjects With Genotype 1a Chronic Hepatitis C Virus Infection (GEODE II)
Phase of Trial: Phase III
Latest Information Update: 24 Oct 2017
At a glance
- Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Registrational; Therapeutic Use
- Acronyms GEODE II
- Sponsors AbbVie
- 04 Jan 2017 Status changed from active, no longer recruiting to completed.
- 08 Nov 2016 Planned primary completion date changed from 1 Oct 2016 to 1 Dec 2016.
- 09 Aug 2016 Planned End Date changed from 1 Oct 2016 to 1 Dec 2016.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History